Yazar "Mohammadnejad, Javad" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Investigating monoclonal antibody against cytokeratin 19 tumor marker
    (Bmc, 2025) Momeni-Moghaddam, Mohammad Amin; Mohammadnejad, Javad; Ghahremani, Hossein; Khaghani, Shahnaz; Moradi, Nariman; Daemi, Amin; Ozbolat, Guluzar
    Cytokeratin 19 (CK 19) is a member of the intermediate filaments that are widely expressed in thyroid, breast, colon, small and non-small cell lung, and prostate cancer cells. This paper aims to produce the monoclonal antibody against CK 19. Recombinant CK 19 was used to immunize of two 6-8 weeks old female Balb/c mice. For the first injection, recombinant antigen was mixed with the complete Freund ' s Adjuvant, and for the second and third injections, mixed with the Incomplete Freund ' s Adjuvant. Injections were performed at intervals of 15 days. Four days after the third injection, titration of mice serum was determined using indirect ELISA and better-immunized mice selected for fusion. Intravenous (IV) injection was performed 4 days before the fusion. The spleen cells of the mice were fused with sp2/0 cells using 50% v/v polyethylene glycol (PEG) and cells were suspended in HAT (Hypoxanthine-Aminopterin-Thymidine) medium. Supernatants of hybridoma cells were screened for antibody secretion by indirect ELISA. Two stable hybridomas were obtained among 78 hybridoma clones that reacted with the recombinant CK 19 by indirect ELISA. These hybridoma cells were monoclonal twice by limiting dilution. Besides, immunization by recombinant CK 19 led to the obtaining of two stable monoclonal antibodies against this antigen. Western blotting with HT-29 cell line demonstrated a band of upper than 43 kDa. Result of HepG2 indicated a band of lower than 45 kDa while MCF7 bands of 45 kDa and higher were observed for MCF7. A431 cell line was epidermoid carcinoma, as CK 19 did not exist in the epidermis, therefore no band was observed in A431 cell line.
  • [ X ]
    Öğe
    Investigating the Effects of Curcumin on Lipid Metabolism and Cell Viability in HepG2 Cells: Potential Therapeutic Implications for Nonalcoholic Fatty Liver Disease
    (Wiley, 2025) Qaleban, Faeze; Mohammadnejad, Javad; Daemi, Amin; Ozbolat, Guluzar; Dogus, Yusuf
    Metabolic dysfunction-associated steatotic liver disease (MASLD), poses a significant global health challenge, necessitating novel therapeutic strategies. This study investigates examines the efficacy of curcumin (Cur), a natural bioactive compound, in suppressing inhibiting the proliferation of hepatocellular carcinoma proliferation and reducing lipid accumulation in vitro. HepG2 cells were treated with Cur (1.25-10 mu g/mL) for 24-72 h, revealing a dose- and time-dependent reduction in viability, with an IC50 of 10 mu g/mL at 72 h. Oil Red O staining demonstrated Cur's lipid-lowering effects, reducing lipid content by 57% at 5 mu g/mL and 78% at 10 mu g/mL, suggesting enhanced efficacy at higher concentrations. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) analysis revealed that Cur downregulated key lipogenic regulators Peroxisome proliferator-activated receptor gamma (PPAR gamma) and CCAAT/enhancer-binding protein alpha (C/EBP-alpha) by 2.3- and 1.8-fold, respectively, while modulating 14-3-3 gamma/beta expression, implicating these pathways in its mechanism. These findings highlight Cur's potential to attenuate hepatic lipid accumulation and cancer cell growth in vitro, warranting further validation in primary hepatocytes and preclinical models to advance its therapeutic prospects for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
  • [ X ]
    Öğe
    Sodium butyrate entrapped chitosan-PAMAM for suppression of colorectal cancer cells
    (Bmc, 2025) Al-Zihaymee, Ruaa Mahdi Mayih; Mohammadnejad, Javad; Narmani, Asghar; Jafar, Hanieh; Ozbolat, Guluzar; Daemi, Amin; Dogus, Yusuf
    Objective Cancer treatment is a major concern of health worldwide. Nowadays, colorectal cancer is one of the most prevalent diseases throughout the globe. Therefore, novel cancer treatment modalities are required to stop cancer. Thus, this paper aims to develop a novel drug delivery system (DDS) based on Chitosan (CS), polyamidoamine (PAMAM G4), and Nanoparticles (NP) for efficient delivery of sodium butyrate (NB) and Fe2O3 to SW480 colorectal cancer cells. Methods To do so, after characterizing the nanocarrier with FT-IR, DLS, TEM, and TGA, nanometric size (40-65 nm), high drug content (23% Fe2O3 and 3% NB), controlled NB release (4% within 2 h), and pH-sensitive NB release (35% within 2 h) were measured for CS-PAMAM-Fe2O3-NB. Result In biomedical tests, MTT assay indicated 10% (after 24 h), 8% (after 48 h), and 7% (after 72 h) cell viabilities for 200 nM concentration of CS-PAMAM-Fe2O3-NB nanocarrier on SW480 cells while pure NB did not have potential toxicity on cancer cells. IC50 determined for 25 nM after 24 h. qRT-PCR test indicated a 7-fold and 10-fold increase for Caspase9 and Bax apoptotic genes whereas 0.3-fold expression quantified for Bcl2 anti-apoptotic gene. Conclusion According to the obtained results, it can be concluded that the fabricated nanocarrier would be a potential DDS against colorectal cancer cells. The results of these biomedical tests have approved potential the ability of the synthesized DDS in the inhibition of colorectal cancer cells. High biocompatibility was shown in MSC normal cells which further verified the efficiency of CS-PAMAM-Fe2O3-NB.